Disc Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Disc Medicine, Inc. (IRON) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 0 shares for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2024-08-08
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2023 was 1.92K shares, a 76.79% decline from fiscal 2022.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 8.25K shares, a 44.12% decline from fiscal 2021.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2021 was 14.77K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 0.00 shares 10-Q · filed 2024-08-08 | 0.00 shares derived: sum of 3 quarters · filed 2024-08-08 | 0.00 shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | 0.00 shares derived: sum of 2 quarters · filed 2024-05-09 | 0.00 shares derived: sum of 3 quarters · filed 2024-05-09 | 958.00 shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-21 | 958.00 shares derived: sum of 3 quarters · filed 2024-08-08 | 1.92K shares 10-K · filed 2024-03-21 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 958.00 shares derived: sum of 2 quarters · filed 2024-08-08 | 1.92K shares 10-Q · filed 2023-11-09 | 3.32K shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-06-30 | 958.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.92K shares 10-Q · filed 2024-08-08 | 3.32K shares derived: sum of 3 quarters · filed 2024-08-08 | 5.60K shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | 958.00 shares 10-Q · filed 2024-05-09 | 2.36K shares derived: sum of 2 quarters · filed 2024-05-09 | 4.64K shares derived: sum of 3 quarters · filed 2024-05-09 | 6.93K shares derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | 1.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 3.68K shares derived: sum of 2 quarters · filed 2024-03-21 | 5.97K shares derived: sum of 3 quarters · filed 2024-03-21 | 8.25K shares 10-K · filed 2024-03-21 | |
| 2022-09-30 | 2.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 4.57K shares derived: sum of 2 quarters · filed 2023-11-09 | 6.85K shares 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 2.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 4.57K shares 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | 2.29K shares 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | 14.77K shares 10-K · filed 2023-03-31 | 35.57K shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |